Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Signs Deal with Germany’s Metabion

Premium

Sequenom of San Diego has announced an agreement to sell its MassArray system to Metabion.

 

Terms of the deal were not disclosed.

 

Metabion of Munich will use the system to monitor its oligonucleotide production while providing Sequenom with a source for oligonucleotides, an element in assay development for genotyping technologies.

 

Separately, Sequenom said it had agreed to screen DNA samples linked to type 2 diabetes mellitus provided by the US National Institute of Diabetes and Digestive Kidney Diseases, a division of the USNational Institutes of Health.

 

Sequenom CEO Toni Schuh said the deal would expand the commercial relationship between Sequenom and the National Institutes of Health but he did not offer specifics. Sequenom said it expects current projects from the NIH to generate $500,000 in revenue this year for the company.

 

In addition, Sequenom also recently launched its 384 SpectroChip, which is designed to increase throughput and reduce the costs associated with the analysis of SNPs.

 

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.